Quantification of cancer risk in glomerulonephritis

BMC Nephrology

Table 6 Distribution of 378 observed minus expected cases between −1 and 10 years after biopsy according to cancer diagnosis (%)

Cancer Diagnosis	Number	MCD	End	FSGS	MesPGN	MN	MPGN	FSPGN	Focal	NCGN	Unclassified	ANCAV	Typical GN in the literature [4]
Lung	37	8	6	16	17	23	11			6			MN, MCD, MPGN, MesPGN, FSGS, NCGN
Prostate	33					16		20		28	15	8	MCD, NCGN
Renal	30				16						78		NCGN, MesPGN, MCD, FSGS, MPGN
Non-Hodgkin	22	15					30				36	6	MN, MCD, MPGN, FSGS, NCGN
Myeloma	37	7		5	17		8				55
Leukemia	15					16	23	10	10		22	19	MN, MCD, MPGN, FSGS, NCGN
Skin (non-melanoma)	152	7		6	16	12	8	10		12	11	10	MN
Unclassified	56			11	20	19	5		6		26

Cancer diagnoses with significantly raised incidence only. Negative figures excluded for this analysis. Only figures > 5% shown. MCD: minimal change disease
MN membranous nephropathy, FSGS focal segmental glomerulosclerosis, MesPGN mesangioproliferative GN, MPGN Membranoproliferative GN, FSPGN focal segmental proliferative GN, NCGN necrotizing and crescentic GN

ISSN: 1471-2369